Abstract
Summary
Tocotrienols have shown bone-protective effect in animals. This study showed that a 12-week tocotrienol supplementation decreased concentrations of bone resorption biomarker and bone remodeling regulators via suppressing oxidative stress in postmenopausal osteopenic women.
Introduction
Tocotrienols (TT) have been shown to benefit bone health in ovariectomized animals, a model of postmenopausal women. The purpose of this study was to evaluate the effect of 12-week TT supplementation on bone markers (serum bone-specific alkaline phosphatase (BALP), urine N-terminal telopeptide (NTX), serum soluble receptor activator of nuclear factor-kappaB ligand (sRANKL), and serum osteoprotegerin (OPG)), urine calcium, and an oxidative stress biomarker (8-hydroxy-2′-deoxyguanosine (8-OHdG)) in postmenopausal women with osteopenia.
Methods
Eighty-nine postmenopausal osteopenic women (59.7 ± 6.8 year, BMI 28.7 ± 5.7 kg/m2) were randomly assigned to three groups: (1) placebo (430 mg olive oil/day), (2) low TT (430 mg TT/day, 70% purity), and (3) high TT (860 mg TT/day, 70% purity). TT, an extract from annatto seed with 70% purity, consisted of 90% delta-TT and 10% gamma-TT. Overnight fasting blood and urine samples were collected at baseline, 6, and 12 weeks for biomarker analyses. Eighty-seven subjects completed the 12-week study.
Results
Relative to the placebo group, there were marginal decreases in serum BALP level in the TT-supplemented groups over the 12-week study period. Significant decreases in urine NTX levels, serum sRANKL, sRANKL/OPG ratio, and urine 8-OHdG concentrations and a significant increase in BALP/NTX ratio due to TT supplementation were observed. TT supplementation did not affect serum OPG concentrations or urine calcium levels throughout the study period. There were no significant differences in NTX level, BALP/NTX ratio, sRANKL level, and sRANKL/OPG ratio between low TT and high TT groups.
Conclusions
Twelve-week annatto-extracted TT supplementation decreased bone resorption and improved bone turnover rate via suppressing bone remodeling regulators in postmenopausal women with osteopenia. Such osteoprotective TT’s effects may be, in part, mediated by an inhibition of oxidative stress.
Trial registration
ClinicalTrials.gov identifier: NCT02058420. Title: Tocotrienols and bone health of postmenopausal women.
Similar content being viewed by others
References
Wauquier F, Leotoing L, Coxam V, Guicheux J, Wittrant Y (2009) Oxidative stress in bone remodelling and disease. Trends Mol Med 15(10):468–477. https://doi.org/10.1016/j.molmed.2009.08.004
NIH (2001) Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 285(6):785–795
National Osteoporosis Foundation. American’s bone health: the state of osteoporosis and low bone mass in our nation. Washington, DC: National Osteoporosis Foundation, 2002;1–55
Rizzoli R, Reginster JY (2011) Adverse drug reactions to osteoporosis treatments. Expert Rev Clin Pharmacol 4(5):593–604. https://doi.org/10.1586/ecp.11.42
Shahidi F, de Camargo AC (2016) Tocopherols and tocotrienols in common and emerging dietary sources: occurrence, applications, and health benefits. Int J Mol Sci 17(10):E1745
Nizar AM, Nazrun AS, Norazlina M, Norliza M, Ima Nirwana S (2011) Low dose of tocotrienols protects osteoblasts against oxidative stress. Clin Ter 162(6):533–538
Ha H, Lee JH, Kim HN, Lee ZH (2011) Alpha-tocotrienol inhibits osteoclastic bone resorption by suppressing RANKL expression and signaling and bone resorbing activity. Biochem Biophys Res Commun 406(4):546–551. https://doi.org/10.1016/j.bbrc.2011.02.085
Brooks R, Kalia P, Ireland DC, Beeton C, Rushton N (2011) Direct inhibition of osteoclast formation and activity by the vitamin E isomer gamma-tocotrienol. Int J Vitam Nutr Res 81(6):358–367. https://doi.org/10.1024/0300-9831/a000087
Gürkan L, Ekeland A, Gautvik KM, Langeland N, Rønningen H, Solheim LF (1986) Bone changes after castration in rats. A model for osteoporosis. Acta Orthop Scand 57(1):67–70. https://doi.org/10.3109/17453678608993219
Soelaiman IN, Ming W, Abu Bakar R, Hashnan NA, Mohd Ali H, Mohamed N, Muhammad N, Shuid AN (2012) Palm tocotrienol supplementation enhanced bone formation in oestrogen-deficient rats. Int J Endocrinol 2012:532862
Deng L, Ding Y, Peng Y, Wu Y, Fan J, Li W, Yang R, Yang M, Fu Q (2014) γ-Tocotrienol protects against ovariectomy-induced bone loss via mevalonate pathway as HMG-CoA reductase inhibitor. Bone 67:200–207. https://doi.org/10.1016/j.bone.2014.07.006
Abdul-Majeed S, Mohamed N, Soelaiman IN (2012) Effects of tocotrienol and lovastatin combination on osteoblast and osteoclast activity in estrogen-deficient osteoporosis. Evid Based Complement Alternat Med 2012:960742
Aktifanus AT, Shuid AN, Rashid NHA, Ling TH, Loong CY, Saat NM, Muhammad N, Mohamed N, Soelaiman IN (2012) Comparison of the effects of tocotrienol and estrogen on the bone markers and dynamic changes in postmenopausal osteoporosis rat model. Asian J Anim Vet Adv 7:225–234
Shibata A, Nakagawa K, Sookwong P, Tsuduki T, Asai A, Miyazawa T (2010) α-Tocopherol attenuates the cytotoxic effect of δ-tocotrienol in human colorectal adenocarcinoma cells. Biochem Biophys Res Commun 397(2):214–219. https://doi.org/10.1016/j.bbrc.2010.05.087
Shen CL, Klein A, Chin KY, Mo H, Tsai P, Yang RS, Chyu MC, Ima-Nirwana S (2017) Tocotrienols for bone health: a translational approach. Ann N Y Acad Sci 1401:150–165.
Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22(3):659–661. https://doi.org/10.1096/fj.07-9574LSF
Kruger MC, Ha PC, Todd JM, Kuhn-Sherlock B, Schollum LM, Ma J, Qin G, Lau E (2012) High-calcium, vitamin D fortified milk is effective in improving bone turnover markers and vitamin D status in healthy postmenopausal Chinese women. Eur J Clin Nutr 66(7):856–861. https://doi.org/10.1038/ejcn.2012.54
Li Z, Karp H, Zerlin A, Lee TY, Carpenter C, Heber D (2010) Absorption of silicon from artesian aquifer water and its impact on bone health in postmenopausal women: a 12 week pilot study. Nutr J 9(1):44. https://doi.org/10.1186/1475-2891-9-44
Shen CL, Mo H, Yang S, Wang S, Felton CK, Tomison MD, Soelaiman IN (2016) Safety and efficacy of tocotrienol supplementation for bone health in postmenopausal women: protocol for a dose-response double-blinded placebo-controlled randomised trial. BMJ Open 6(12):e012572. https://doi.org/10.1136/bmjopen-2016-012572
Iwamoto J, Takada T (2015) Effect of minodronate on the speed of sound of the calcaneus in postmenopausal women with an increased risk of fractures: a clinical practice-based observational study. J Chin Med Assoc 78(10):591–596. https://doi.org/10.1016/j.jcma.2015.06.010
Naylor KE, Jacques RM, Peel NF, Gossiel F, Eastell R (2016) Response of bone turnover markers to raloxifene treatment in postmenopausal women with osteopenia. Osteoporos Int 27(8):2585–2592. https://doi.org/10.1007/s00198-016-3573-z
Norazlina M, Ima-Nirwana S, Gapor MT, Khalid BA (2000) Palm vitamin E is comparable to alpha-tocopherol in maintaining bone mineral density in ovariectomised female rats. Exp Clin Endocrinol Diabetes 108(04):305–310. https://doi.org/10.1055/s-2000-7758
Zittermann A, Geppert J, Baier S, Zehn N, Gouni-Berthold I, Berthold HK, Reinsberg J, Stehle P (2004) Short-term effects of high soy supplementation on sex hormones, bone markers, and lipid parameters in young female adults. Eur J Nutr 43(2):100–108. https://doi.org/10.1007/s00394-004-0447-5
Shen CL, Chyu MC, Yeh JK, Zhang Y, Pence BC, Felton CK, Brismée JM, Arjmandi BH, Doctolero S, Wang JS (2012) Effect of green tea and Tai Chi on bone health in postmenopausal osteopenic women: a 6-month randomized placebo-controlled trial. Osteoporos Int 23(5):1541–1552. https://doi.org/10.1007/s00198-011-1731-x
Clarke BL, Khosla S (2010) Physiology of bone loss. Radiol Clin N Am 48(3):483–495. https://doi.org/10.1016/j.rcl.2010.02.014
Tchernof A, Poehlman ET, Després JP (2000) Body fat distribution, the menopause transition, and hormone replacement therapy. Diabetes Metab 26(1):12–20
Maltais ML, Desroches J, Dionne IJ (2009) Changes in muscle mass and strength after menopause. J Musculoskelet Neuronal Interact 9(4):186–197
Fu X, Ma X, Lu H, He W, Wang Z, Zhu S (2011) Associations of fat mass and fat distribution with bone mineral density in pre- and postmenopausal Chinese women. Osteoporos Int 22(1):113–119. https://doi.org/10.1007/s00198-010-1210-9
Nelson CA, Warren JT, Wang MWH, Teitelbaum SL, Fremont DH (2012) RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor. Structure 20(11):1971–1982. https://doi.org/10.1016/j.str.2012.08.030
Wada T, Nakashima T, Hiroshi N, Penninger JM (2006) RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12(1):17–25. https://doi.org/10.1016/j.molmed.2005.11.007
Weichhaus M, Segaran P, Renaud A, Geerts D, Connelly L (2014) Osteoprotegerin expression in triple-negative breast cancer cells promotes metastasis. Cancer Med 3(5):1112–1125. https://doi.org/10.1002/cam4.277
Boyce BF, Xing L (2008) Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 473(2):139–146. https://doi.org/10.1016/j.abb.2008.03.018
Boyce BF, Xing L (2007) Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 9 Suppl 1:S1. Review
Raisz LG (2005) Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115(12):3318–3325. https://doi.org/10.1172/JCI27071
Kearns AE, Khosla S, Kostenuik PJ (2008) Receptor activator of nuclear factor кB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocrine Rev 29(2):155–928. https://doi.org/10.1210/er.2007-0014
Vega D, Maalouf NM, Sakhaee K (2007) The role of receptor activator of nuclear factor-휅B (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 92(12):4514–4521. https://doi.org/10.1210/jc.2007-0646
Nabipour I, Larijani B, Vahdat K, Assadi M, Jafari SM, Ahmadi E, Movahed A, Moradhaseli F, Sanjdideh Z, Obeidi N, Amiri Z (2009) Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory. Menopause 16(5):950–955. https://doi.org/10.1097/gme.0b013e3181a181b8
Garrett JR, Boyce BF, Oreffo RO, Bonewald L, Poser J, Mundy GR (1990) Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest 85(3):632–639. https://doi.org/10.1172/JCI114485
Bai XC, Lu D, Bai J, Zheng H, Ke ZY, Li XM, Luo SQ (2004) Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-kappaB. Biochem Biophys Res Commun 314(1):197–207. https://doi.org/10.1016/j.bbrc.2003.12.073
Cervellati C, Romani A, Cremonini E, Bergamini CM, Fila E, Squerzanti M, Greco P, Massari L, Bonaccorsi G (2016) Higher urinary levels of 8-hydroxy-2′-deoxyguanosine are associated with a worse RANKL/OPG ratio in postmenopausal women with osteopenia. Oxidative Med Cell Longev 2016:6038798
Wang Y, Park NY, Jang Y, Ma A, Jiang Q (2015) Vitamin E γ-tocotrienol inhibits cytokine-stimulated NF-κB activation by induction of anti-inflammatory A20 via stress adaptive response due to modulation of sphingolipids. J Immunol 195(1):126–133. https://doi.org/10.4049/jimmunol.1403149
Abd Manan N, Mohamed N, Shuid AN (2012) Effects of low-dose versus high-dose γ-tocotrienol on the bone cells exposed to the hydrogen peroxide-induced oxidative stress and apoptosis. Evid Based Complement Alternat Med 2012:680834
Qureshi AA, Khan DA, Mahjabeen W, Trias AM, Silswal N, Qureshi N (2015) Impact of δ-Tocotrienol on inflammatory biomarkers and oxidative stress in hypercholesterolemic subjects. J Clin Exp Cardiolog 6(4):1000367
Qureshi AA, Khan DA, Mahjabeen W, Qureshi N (2015) Dose-dependent modulation of lipid parameters, cytokines and RNA by δ-tocotrienol in hypercholesterolemic subjects restricted to AHA Step-1 diet. Br J Med Medical Res 6(4):351–366. https://doi.org/10.9734/BJMMR/2015/13820
Acknowledgements
This study was supported by American River Nutrition, Inc., Hadley, MA.
Funding
This study is funded by American River Nutrition, Inc.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
None.
Rights and permissions
About this article
Cite this article
Shen, CL., Yang, S., Tomison, M.D. et al. Tocotrienol supplementation suppressed bone resorption and oxidative stress in postmenopausal osteopenic women: a 12-week randomized double-blinded placebo-controlled trial. Osteoporos Int 29, 881–891 (2018). https://doi.org/10.1007/s00198-017-4356-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-017-4356-x